Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy.Scope:
Proposals should focus on the following:
As relevant, the proposed activities should address sex and gender specific aspects[[See definition of the 'gender dimension approach' in the introduction of this Work Programme part.]].
Activities are expected to commence at Technology Readiness Levels 3/4 and reach 5/6.
The Commission considers that proposals requesting a contribution from the EU between EUR 5 and 7 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.Expected Impact:
Proposals should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.